BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27716362)

  • 21. Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.
    Fanourakis G; Tosios K; Papanikolaou N; Chatzistamou I; Xydous M; Tseleni-Balafouta S; Sklavounou A; Voutsinas GE; Vastardis H
    Exp Mol Pathol; 2016 Dec; 101(3):314-319. PubMed ID: 27818121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
    Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
    Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations.
    Shen B; Chapman JH; Custance MF; Tricola GM; Jones CE; Furano AV
    Elife; 2020 Jan; 9():. PubMed ID: 31904337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
    Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
    Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic inhibitors of APOBEC3B-induced mutagenesis.
    Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
    Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer.
    Harris RS
    Breast Cancer Res; 2015 Jan; 17(1):8. PubMed ID: 25848704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.
    Taylor BJ; Nik-Zainal S; Wu YL; Stebbings LA; Raine K; Campbell PJ; Rada C; Stratton MR; Neuberger MS
    Elife; 2013 Apr; 2():e00534. PubMed ID: 23599896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
    Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
    BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers.
    Chou WC; Chen WT; Hsiung CN; Hu LY; Yu JC; Hsu HM; Shen CY
    Sci Rep; 2017 Mar; 7():44089. PubMed ID: 28276478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOBEC3B is an enzymatic source of mutation in breast cancer.
    Burns MB; Lackey L; Carpenter MA; Rathore A; Land AM; Leonard B; Refsland EW; Kotandeniya D; Tretyakova N; Nikas JB; Yee D; Temiz NA; Donohue DE; McDougle RM; Brown WL; Law EK; Harris RS
    Nature; 2013 Feb; 494(7437):366-70. PubMed ID: 23389445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
    Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
    Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PrimPol prevents APOBEC/AID family mediated DNA mutagenesis.
    Pilzecker B; Buoninfante OA; Pritchard C; Blomberg OS; Huijbers IJ; van den Berk PC; Jacobs H
    Nucleic Acids Res; 2016 Jun; 44(10):4734-44. PubMed ID: 26926109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
    Schmitt C; Lucius R; Synowitz M; Held-Feindt J; Hattermann K
    Oncol Rep; 2018 Nov; 40(5):2742-2749. PubMed ID: 30226610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
    Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
    Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
    Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
    Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
    PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
    Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
    Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clearing of Foreign Episomal DNA from Human Cells by CRISPRa-Mediated Activation of Cytidine Deaminases.
    Brezgin S; Kostyusheva A; Ponomareva N; Volia V; Goptar I; Nikiforova A; Shilovskiy I; Smirnov V; Kostyushev D; Chulanov V
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion.
    Nowarski R; Kotler M
    Cancer Res; 2013 Jun; 73(12):3494-8. PubMed ID: 23598277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.